Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront

Janux Therapeutics, Inc.

2025-FY EPS reported -$1.83 revenue$10,000,000

Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
R&D expenses $125.9M for FY2025 vs $68.4M; net loss $113.6M vs $69.0M in 2024.
Entered collaboration with Bristol Myers Squibb for tumor-activated therapeutic; $50M upfront + up to $800M milestones.
Appointed Dr. William Go as CMO; JANX007/008/011 trials continue enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.